Quantitative Benefit–Risk Evaluation of Rivaroxaban in Arterial Revascularization: The VOYAGER PAD Trial

Journal of the American Heart Association

13, e032782

DOI: 10.1161/jaha.123.032782

Citation Report

#	Article	IF	Citations
1	Surgical Decision-Making. , 2024, .		7
2	Anticoagulants: From Chance Discovery to Structure-Based Design. Pharmacological Reviews, 2025, 77, 100037.	18.6	5
3	Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism. Drugs and Aging, 2025, 42, 469-484.	4.9	3
4	Expanding the Use and Interpretation of Patient-Centric Cardiovascular Clinical Trial Endpoints. Journal of Clinical and Translational Science, 2025, 9, e151.	2.4	2
5	Dual Versus Single Antiplatelet Therapy After Lower Extremity Revascularization in Peripheral Artery Disease: A Systematic Review and Meta-Analysis. World Journal of Cardiology, 2025, 17, 111941.	2.5	2
6	Venous Thromboembolism in Patients Receiving Rivaroxaban Plus Aspirin or Standard Treatment After Lower Limb Revascularization-Rationale and Design of the RESOLUTION Trial. Annals of Vascular Surgery, 2026, 124, 22-27.	1.8	0
7	Rivaroxaban Does Not Alter Carotid Plaque Echolucency, Volume, or Neovascularisation. European Journal of Vascular and Endovascular Surgery, 2026, 71, 354-363.	3.2	2
8	Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies. Journal of Clinical Medicine, 2026, 15, 2325.	3.8	3
9	Peripheral Artery Disease Treatment: Scoping Review With ☸SAIMSARA. , 2026, .		0
10	Benefit-Risk Profile Comparison Between Dupilumab and Upadacitinib: A Structured Benefit-Risk Assessment of the Heads Up Trial. Journal of Dermatological Treatment, 2026, 37, 2675726.	3.8	1
11	Antithrombotic Therapy After Lower Limb EndoVascular Interventions: Are We Overtreating or Undertreating? - A Narrative Review. Cardiology in Review, 2026, .	1.7	0